nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—Protein Kinase Inhibitors—Vemurafenib—skin cancer	0.599	1	CiPCiCtD
Pazopanib—ABCG2—Vismodegib—skin cancer	0.0282	0.144	CbGbCtD
Pazopanib—ABCG2—Vemurafenib—skin cancer	0.0223	0.113	CbGbCtD
Pazopanib—CYP1A2—Imiquimod—skin cancer	0.0167	0.0854	CbGbCtD
Pazopanib—CYP2C8—Vismodegib—skin cancer	0.015	0.0765	CbGbCtD
Pazopanib—ABCG2—Dactinomycin—skin cancer	0.0148	0.0754	CbGbCtD
Pazopanib—ABCB1—Vismodegib—skin cancer	0.0102	0.0518	CbGbCtD
Pazopanib—ABCG2—Fluorouracil—skin cancer	0.01	0.051	CbGbCtD
Pazopanib—CYP1A2—Vemurafenib—skin cancer	0.00918	0.0468	CbGbCtD
Pazopanib—CYP3A4—Temozolomide—skin cancer	0.00877	0.0447	CbGbCtD
Pazopanib—CYP3A4—Imiquimod—skin cancer	0.00877	0.0447	CbGbCtD
Pazopanib—ABCG2—Docetaxel—skin cancer	0.00764	0.0389	CbGbCtD
Pazopanib—CYP2D6—Vemurafenib—skin cancer	0.00756	0.0386	CbGbCtD
Pazopanib—CYP1A2—Dacarbazine—skin cancer	0.00703	0.0359	CbGbCtD
Pazopanib—CYP3A4—Vismodegib—skin cancer	0.00608	0.031	CbGbCtD
Pazopanib—ABCB1—Dactinomycin—skin cancer	0.00533	0.0272	CbGbCtD
Pazopanib—CYP2C8—Fluorouracil—skin cancer	0.00533	0.0272	CbGbCtD
Pazopanib—CYP3A4—Vemurafenib—skin cancer	0.00481	0.0245	CbGbCtD
Pazopanib—CYP1A2—Fluorouracil—skin cancer	0.00412	0.021	CbGbCtD
Pazopanib—ABCB1—Docetaxel—skin cancer	0.00275	0.014	CbGbCtD
Pazopanib—FGF1—dermis—skin cancer	0.00191	0.0329	CbGeAlD
Pazopanib—CYP3A4—Docetaxel—skin cancer	0.00165	0.00841	CbGbCtD
Pazopanib—FGFR3—appendage—skin cancer	0.00139	0.024	CbGeAlD
Pazopanib—PDGFRA—penis—skin cancer	0.00122	0.021	CbGeAlD
Pazopanib—FGFR3—skin epidermis—skin cancer	0.00116	0.0199	CbGeAlD
Pazopanib—FGF1—appendage—skin cancer	0.000964	0.0166	CbGeAlD
Pazopanib—KDR—hindlimb—skin cancer	0.000832	0.0143	CbGeAlD
Pazopanib—FGFR3—hair follicle—skin cancer	0.000826	0.0142	CbGeAlD
Pazopanib—FGF1—skin epidermis—skin cancer	0.000802	0.0138	CbGeAlD
Pazopanib—FGFR2—skin epidermis—skin cancer	0.000757	0.0131	CbGeAlD
Pazopanib—LIMK2—hair follicle—skin cancer	0.000717	0.0124	CbGeAlD
Pazopanib—KDR—appendage—skin cancer	0.000713	0.0123	CbGeAlD
Pazopanib—FGF1—nerve—skin cancer	0.000683	0.0118	CbGeAlD
Pazopanib—SH2B3—nipple—skin cancer	0.000669	0.0115	CbGeAlD
Pazopanib—FLT4—endothelium—skin cancer	0.000655	0.0113	CbGeAlD
Pazopanib—MAP3K9—epithelium—skin cancer	0.000637	0.011	CbGeAlD
Pazopanib—FLT4—blood vessel—skin cancer	0.000604	0.0104	CbGeAlD
Pazopanib—FGF1—endothelium—skin cancer	0.000582	0.01	CbGeAlD
Pazopanib—RIOK2—nipple—skin cancer	0.00056	0.00965	CbGeAlD
Pazopanib—MAP3K9—mammalian vulva—skin cancer	0.000553	0.00953	CbGeAlD
Pazopanib—FGF1—blood vessel—skin cancer	0.000537	0.00925	CbGeAlD
Pazopanib—KIT—skin epidermis—skin cancer	0.000526	0.00907	CbGeAlD
Pazopanib—FLT1—endothelium—skin cancer	0.000509	0.00878	CbGeAlD
Pazopanib—PI4KB—nipple—skin cancer	0.000495	0.00854	CbGeAlD
Pazopanib—LIMK2—nipple—skin cancer	0.000486	0.00838	CbGeAlD
Pazopanib—MAP3K9—female reproductive system—skin cancer	0.000473	0.00816	CbGeAlD
Pazopanib—FLT1—blood vessel—skin cancer	0.00047	0.0081	CbGeAlD
Pazopanib—ITK—mammalian vulva—skin cancer	0.000456	0.00786	CbGeAlD
Pazopanib—PIP4K2C—nipple—skin cancer	0.000434	0.00749	CbGeAlD
Pazopanib—KDR—endothelium—skin cancer	0.000431	0.00742	CbGeAlD
Pazopanib—TAOK1—mammalian vulva—skin cancer	0.000415	0.00715	CbGeAlD
Pazopanib—ITK—lymphoid tissue—skin cancer	0.000405	0.00698	CbGeAlD
Pazopanib—LYN—connective tissue—skin cancer	0.000399	0.00688	CbGeAlD
Pazopanib—KDR—blood vessel—skin cancer	0.000397	0.00685	CbGeAlD
Pazopanib—FGFR3—connective tissue—skin cancer	0.000397	0.00684	CbGeAlD
Pazopanib—MAP3K9—head—skin cancer	0.000395	0.00682	CbGeAlD
Pazopanib—SH2B3—mammalian vulva—skin cancer	0.000391	0.00673	CbGeAlD
Pazopanib—LCK—nipple—skin cancer	0.000386	0.00665	CbGeAlD
Pazopanib—FGF1—neck—skin cancer	0.000384	0.00662	CbGeAlD
Pazopanib—KIT—endothelium—skin cancer	0.000382	0.00658	CbGeAlD
Pazopanib—FGFR3—epithelium—skin cancer	0.000377	0.0065	CbGeAlD
Pazopanib—BMPR1B—epithelium—skin cancer	0.000373	0.00643	CbGeAlD
Pazopanib—FGFR2—neck—skin cancer	0.000363	0.00625	CbGeAlD
Pazopanib—FGFR3—skin of body—skin cancer	0.000358	0.00618	CbGeAlD
Pazopanib—TAOK1—female reproductive system—skin cancer	0.000355	0.00612	CbGeAlD
Pazopanib—KIT—blood vessel—skin cancer	0.000352	0.00607	CbGeAlD
Pazopanib—SH2B3—lymphoid tissue—skin cancer	0.000347	0.00598	CbGeAlD
Pazopanib—PDGFRB—blood vessel—skin cancer	0.000344	0.00593	CbGeAlD
Pazopanib—FLT1—nipple—skin cancer	0.00034	0.00586	CbGeAlD
Pazopanib—FLT1—neck—skin cancer	0.000336	0.00579	CbGeAlD
Pazopanib—EPHB6—nipple—skin cancer	0.000336	0.00579	CbGeAlD
Pazopanib—AURKC—female reproductive system—skin cancer	0.000329	0.00568	CbGeAlD
Pazopanib—FGFR3—mammalian vulva—skin cancer	0.000327	0.00564	CbGeAlD
Pazopanib—RIOK2—mammalian vulva—skin cancer	0.000327	0.00564	CbGeAlD
Pazopanib—TAOK3—nipple—skin cancer	0.00032	0.00552	CbGeAlD
Pazopanib—PLK4—lymphoid tissue—skin cancer	0.000312	0.00538	CbGeAlD
Pazopanib—PLK4—female reproductive system—skin cancer	0.000301	0.00519	CbGeAlD
Pazopanib—TAOK1—head—skin cancer	0.000297	0.00512	CbGeAlD
Pazopanib—STK16—lymphoid tissue—skin cancer	0.000295	0.00508	CbGeAlD
Pazopanib—FLT4—epithelium—skin cancer	0.000294	0.00507	CbGeAlD
Pazopanib—STK36—mammalian vulva—skin cancer	0.000294	0.00506	CbGeAlD
Pazopanib—MAP3K2—connective tissue—skin cancer	0.000292	0.00504	CbGeAlD
Pazopanib—LYN—lymphoid tissue—skin cancer	0.000292	0.00503	CbGeAlD
Pazopanib—PI4KB—mammalian vulva—skin cancer	0.000289	0.00499	CbGeAlD
Pazopanib—KDR—nipple—skin cancer	0.000287	0.00495	CbGeAlD
Pazopanib—MAP2K5—nipple—skin cancer	0.000287	0.00495	CbGeAlD
Pazopanib—STK16—female reproductive system—skin cancer	0.000284	0.0049	CbGeAlD
Pazopanib—KDR—neck—skin cancer	0.000284	0.0049	CbGeAlD
Pazopanib—LIMK2—mammalian vulva—skin cancer	0.000284	0.00489	CbGeAlD
Pazopanib—CSF1R—nipple—skin cancer	0.00028	0.00483	CbGeAlD
Pazopanib—FGFR3—female reproductive system—skin cancer	0.00028	0.00483	CbGeAlD
Pazopanib—RIOK2—female reproductive system—skin cancer	0.00028	0.00483	CbGeAlD
Pazopanib—SH2B3—head—skin cancer	0.000279	0.00482	CbGeAlD
Pazopanib—MAP3K19—female reproductive system—skin cancer	0.000277	0.00478	CbGeAlD
Pazopanib—BMPR1B—female reproductive system—skin cancer	0.000277	0.00478	CbGeAlD
Pazopanib—MAP3K9—lymph node—skin cancer	0.000277	0.00477	CbGeAlD
Pazopanib—FGF1—connective tissue—skin cancer	0.000275	0.00474	CbGeAlD
Pazopanib—AURKC—head—skin cancer	0.000275	0.00474	CbGeAlD
Pazopanib—FGF1—epithelium—skin cancer	0.000261	0.0045	CbGeAlD
Pazopanib—FGFR2—connective tissue—skin cancer	0.00026	0.00448	CbGeAlD
Pazopanib—KIT—nipple—skin cancer	0.000254	0.00439	CbGeAlD
Pazopanib—PIP4K2C—mammalian vulva—skin cancer	0.000254	0.00437	CbGeAlD
Pazopanib—LIMK2—lymphoid tissue—skin cancer	0.000252	0.00435	CbGeAlD
Pazopanib—KIT—neck—skin cancer	0.000252	0.00434	CbGeAlD
Pazopanib—FGFR1—mammalian vulva—skin cancer	0.000252	0.00434	CbGeAlD
Pazopanib—STK36—female reproductive system—skin cancer	0.000251	0.00434	CbGeAlD
Pazopanib—PDGFRB—nipple—skin cancer	0.000248	0.00428	CbGeAlD
Pazopanib—FGF1—skin of body—skin cancer	0.000248	0.00428	CbGeAlD
Pazopanib—PI4KB—female reproductive system—skin cancer	0.000248	0.00427	CbGeAlD
Pazopanib—FGFR2—epithelium—skin cancer	0.000247	0.00425	CbGeAlD
Pazopanib—PDGFRB—neck—skin cancer	0.000246	0.00424	CbGeAlD
Pazopanib—LIMK2—female reproductive system—skin cancer	0.000243	0.00419	CbGeAlD
Pazopanib—FLT1—connective tissue—skin cancer	0.000241	0.00415	CbGeAlD
Pazopanib—STK16—head—skin cancer	0.000238	0.0041	CbGeAlD
Pazopanib—LYN—head—skin cancer	0.000235	0.00405	CbGeAlD
Pazopanib—FGFR2—skin of body—skin cancer	0.000235	0.00405	CbGeAlD
Pazopanib—FGFR3—head—skin cancer	0.000234	0.00403	CbGeAlD
Pazopanib—RIOK2—head—skin cancer	0.000234	0.00403	CbGeAlD
Pazopanib—MAP3K19—head—skin cancer	0.000232	0.00399	CbGeAlD
Pazopanib—BMPR1B—head—skin cancer	0.000232	0.00399	CbGeAlD
Pazopanib—FLT1—epithelium—skin cancer	0.000229	0.00394	CbGeAlD
Pazopanib—ITK—lymph node—skin cancer	0.000228	0.00394	CbGeAlD
Pazopanib—TAOK3—connective tissue—skin cancer	0.000227	0.00392	CbGeAlD
Pazopanib—FLT4—lymphoid tissue—skin cancer	0.000227	0.0039	CbGeAlD
Pazopanib—PDGFRA—connective tissue—skin cancer	0.000226	0.00389	CbGeAlD
Pazopanib—LCK—mammalian vulva—skin cancer	0.000225	0.00388	CbGeAlD
Pazopanib—FLT4—female reproductive system—skin cancer	0.000218	0.00377	CbGeAlD
Pazopanib—PIP4K2C—female reproductive system—skin cancer	0.000217	0.00375	CbGeAlD
Pazopanib—EPHB6—skin of body—skin cancer	0.000215	0.00371	CbGeAlD
Pazopanib—MAP3K2—lymphoid tissue—skin cancer	0.000214	0.00368	CbGeAlD
Pazopanib—STK36—head—skin cancer	0.00021	0.00362	CbGeAlD
Pazopanib—TAOK1—lymph node—skin cancer	0.000208	0.00358	CbGeAlD
Pazopanib—PI4KB—head—skin cancer	0.000207	0.00357	CbGeAlD
Pazopanib—MAP3K2—female reproductive system—skin cancer	0.000206	0.00355	CbGeAlD
Pazopanib—KDR—connective tissue—skin cancer	0.000204	0.00351	CbGeAlD
Pazopanib—LIMK2—head—skin cancer	0.000203	0.0035	CbGeAlD
Pazopanib—FGF1—lymphoid tissue—skin cancer	0.000201	0.00347	CbGeAlD
Pazopanib—CSF1R—connective tissue—skin cancer	0.000199	0.00343	CbGeAlD
Pazopanib—FLT1—mammalian vulva—skin cancer	0.000198	0.00342	CbGeAlD
Pazopanib—EPHB6—mammalian vulva—skin cancer	0.000196	0.00338	CbGeAlD
Pazopanib—SH2B3—lymph node—skin cancer	0.000196	0.00337	CbGeAlD
Pazopanib—FGF1—female reproductive system—skin cancer	0.000194	0.00335	CbGeAlD
Pazopanib—KDR—epithelium—skin cancer	0.000193	0.00333	CbGeAlD
Pazopanib—AURKC—lymph node—skin cancer	0.000193	0.00332	CbGeAlD
Pazopanib—STK10—mammalian vulva—skin cancer	0.000188	0.00324	CbGeAlD
Pazopanib—TAOK3—mammalian vulva—skin cancer	0.000187	0.00322	CbGeAlD
Pazopanib—FGFR2—female reproductive system—skin cancer	0.000183	0.00316	CbGeAlD
Pazopanib—FLT4—head—skin cancer	0.000183	0.00315	CbGeAlD
Pazopanib—PIP4K2C—head—skin cancer	0.000182	0.00313	CbGeAlD
Pazopanib—KIT—connective tissue—skin cancer	0.00018	0.00311	CbGeAlD
Pazopanib—CSF1R—skin of body—skin cancer	0.000179	0.00309	CbGeAlD
Pazopanib—PDGFRB—connective tissue—skin cancer	0.000176	0.00304	CbGeAlD
Pazopanib—PLK4—lymph node—skin cancer	0.000176	0.00304	CbGeAlD
Pazopanib—FLT1—lymphoid tissue—skin cancer	0.000176	0.00304	CbGeAlD
Pazopanib—MAP3K2—head—skin cancer	0.000172	0.00297	CbGeAlD
Pazopanib—KIT—epithelium—skin cancer	0.000171	0.00295	CbGeAlD
Pazopanib—FLT1—female reproductive system—skin cancer	0.00017	0.00293	CbGeAlD
Pazopanib—KDR—mammalian vulva—skin cancer	0.000168	0.00289	CbGeAlD
Pazopanib—MAP2K5—mammalian vulva—skin cancer	0.000168	0.00289	CbGeAlD
Pazopanib—PDGFRB—epithelium—skin cancer	0.000167	0.00288	CbGeAlD
Pazopanib—STK10—lymphoid tissue—skin cancer	0.000167	0.00287	CbGeAlD
Pazopanib—STK16—lymph node—skin cancer	0.000166	0.00287	CbGeAlD
Pazopanib—TAOK3—lymphoid tissue—skin cancer	0.000166	0.00286	CbGeAlD
Pazopanib—PDGFRA—lymphoid tissue—skin cancer	0.000165	0.00285	CbGeAlD
Pazopanib—RIOK2—lymph node—skin cancer	0.000164	0.00282	CbGeAlD
Pazopanib—CSF1R—mammalian vulva—skin cancer	0.000164	0.00282	CbGeAlD
Pazopanib—KIT—skin of body—skin cancer	0.000163	0.00281	CbGeAlD
Pazopanib—BMPR1B—lymph node—skin cancer	0.000162	0.00279	CbGeAlD
Pazopanib—FGF1—head—skin cancer	0.000162	0.00279	CbGeAlD
Pazopanib—STK10—female reproductive system—skin cancer	0.000161	0.00277	CbGeAlD
Pazopanib—TAOK3—female reproductive system—skin cancer	0.00016	0.00276	CbGeAlD
Pazopanib—PDGFRA—female reproductive system—skin cancer	0.000159	0.00274	CbGeAlD
Pazopanib—PDGFRB—skin of body—skin cancer	0.000159	0.00274	CbGeAlD
Pazopanib—FGFR2—head—skin cancer	0.000153	0.00264	CbGeAlD
Pazopanib—KDR—lymphoid tissue—skin cancer	0.000149	0.00257	CbGeAlD
Pazopanib—KIT—mammalian vulva—skin cancer	0.000149	0.00256	CbGeAlD
Pazopanib—STK36—lymph node—skin cancer	0.000147	0.00254	CbGeAlD
Pazopanib—CSF1R—lymphoid tissue—skin cancer	0.000145	0.0025	CbGeAlD
Pazopanib—PDGFRB—mammalian vulva—skin cancer	0.000145	0.0025	CbGeAlD
Pazopanib—PI4KB—lymph node—skin cancer	0.000145	0.0025	CbGeAlD
Pazopanib—MAP2K5—female reproductive system—skin cancer	0.000144	0.00248	CbGeAlD
Pazopanib—KDR—female reproductive system—skin cancer	0.000144	0.00248	CbGeAlD
Pazopanib—LIMK2—lymph node—skin cancer	0.000142	0.00245	CbGeAlD
Pazopanib—FLT1—head—skin cancer	0.000142	0.00245	CbGeAlD
Pazopanib—EPHB6—head—skin cancer	0.00014	0.00242	CbGeAlD
Pazopanib—CSF1R—female reproductive system—skin cancer	0.00014	0.00242	CbGeAlD
Pazopanib—CYP1A2—nipple—skin cancer	0.000134	0.00232	CbGeAlD
Pazopanib—STK10—head—skin cancer	0.000134	0.00232	CbGeAlD
Pazopanib—TAOK3—head—skin cancer	0.000134	0.00231	CbGeAlD
Pazopanib—PDGFRA—head—skin cancer	0.000133	0.00229	CbGeAlD
Pazopanib—KIT—lymphoid tissue—skin cancer	0.000132	0.00227	CbGeAlD
Pazopanib—PDGFRB—lymphoid tissue—skin cancer	0.000129	0.00222	CbGeAlD
Pazopanib—FLT4—lymph node—skin cancer	0.000128	0.0022	CbGeAlD
Pazopanib—KIT—female reproductive system—skin cancer	0.000127	0.00219	CbGeAlD
Pazopanib—PIP4K2C—lymph node—skin cancer	0.000127	0.00219	CbGeAlD
Pazopanib—SLCO1B1—female reproductive system—skin cancer	0.000126	0.00218	CbGeAlD
Pazopanib—FGFR1—lymph node—skin cancer	0.000126	0.00217	CbGeAlD
Pazopanib—PDGFRB—female reproductive system—skin cancer	0.000124	0.00214	CbGeAlD
Pazopanib—MAP3K2—lymph node—skin cancer	0.00012	0.00208	CbGeAlD
Pazopanib—KDR—head—skin cancer	0.00012	0.00207	CbGeAlD
Pazopanib—MAP2K5—head—skin cancer	0.00012	0.00207	CbGeAlD
Pazopanib—CSF1R—head—skin cancer	0.000117	0.00202	CbGeAlD
Pazopanib—FGF1—lymph node—skin cancer	0.000114	0.00196	CbGeAlD
Pazopanib—LCK—lymph node—skin cancer	0.000113	0.00195	CbGeAlD
Pazopanib—KIT—head—skin cancer	0.000106	0.00183	CbGeAlD
Pazopanib—PDGFRB—head—skin cancer	0.000104	0.00179	CbGeAlD
Pazopanib—Chills—Bleomycin—skin cancer	9.99e-05	0.00127	CcSEcCtD
Pazopanib—Cardiac failure congestive—Docetaxel—skin cancer	9.95e-05	0.00126	CcSEcCtD
Pazopanib—FLT1—lymph node—skin cancer	9.94e-05	0.00171	CbGeAlD
Pazopanib—Dyspnoea—Imiquimod—skin cancer	9.92e-05	0.00126	CcSEcCtD
Pazopanib—Somnolence—Imiquimod—skin cancer	9.89e-05	0.00125	CcSEcCtD
Pazopanib—Hepatobiliary disease—Temozolomide—skin cancer	9.89e-05	0.00125	CcSEcCtD
Pazopanib—Photosensitivity reaction—Fluorouracil—skin cancer	9.86e-05	0.00125	CcSEcCtD
Pazopanib—Alopecia—Bleomycin—skin cancer	9.83e-05	0.00125	CcSEcCtD
Pazopanib—EPHB6—lymph node—skin cancer	9.82e-05	0.00169	CbGeAlD
Pazopanib—Dyspepsia—Imiquimod—skin cancer	9.8e-05	0.00124	CcSEcCtD
Pazopanib—Erythema—Bleomycin—skin cancer	9.69e-05	0.00123	CcSEcCtD
Pazopanib—Decreased appetite—Imiquimod—skin cancer	9.68e-05	0.00123	CcSEcCtD
Pazopanib—Hot flush—Docetaxel—skin cancer	9.65e-05	0.00122	CcSEcCtD
Pazopanib—Infestation—Fluorouracil—skin cancer	9.64e-05	0.00122	CcSEcCtD
Pazopanib—Infestation NOS—Fluorouracil—skin cancer	9.64e-05	0.00122	CcSEcCtD
Pazopanib—Flushing—Dactinomycin—skin cancer	9.63e-05	0.00122	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Imiquimod—skin cancer	9.61e-05	0.00122	CcSEcCtD
Pazopanib—Fatigue—Imiquimod—skin cancer	9.6e-05	0.00122	CcSEcCtD
Pazopanib—Menopausal symptoms—Docetaxel—skin cancer	9.56e-05	0.00121	CcSEcCtD
Pazopanib—ABCB1—blood vessel—skin cancer	9.53e-05	0.00164	CbGeAlD
Pazopanib—Pain—Imiquimod—skin cancer	9.52e-05	0.00121	CcSEcCtD
Pazopanib—Acute coronary syndrome—Fluorouracil—skin cancer	9.5e-05	0.0012	CcSEcCtD
Pazopanib—Myocardial infarction—Fluorouracil—skin cancer	9.44e-05	0.0012	CcSEcCtD
Pazopanib—Haemoglobin—Temozolomide—skin cancer	9.44e-05	0.0012	CcSEcCtD
Pazopanib—STK10—lymph node—skin cancer	9.41e-05	0.00162	CbGeAlD
Pazopanib—Stomatitis—Fluorouracil—skin cancer	9.39e-05	0.00119	CcSEcCtD
Pazopanib—Haemorrhage—Temozolomide—skin cancer	9.39e-05	0.00119	CcSEcCtD
Pazopanib—TAOK3—lymph node—skin cancer	9.37e-05	0.00162	CbGeAlD
Pazopanib—Asthenia—Vemurafenib—skin cancer	9.36e-05	0.00119	CcSEcCtD
Pazopanib—Hypoaesthesia—Temozolomide—skin cancer	9.34e-05	0.00118	CcSEcCtD
Pazopanib—Chills—Dactinomycin—skin cancer	9.31e-05	0.00118	CcSEcCtD
Pazopanib—PDGFRA—lymph node—skin cancer	9.31e-05	0.00161	CbGeAlD
Pazopanib—Urinary tract disorder—Temozolomide—skin cancer	9.27e-05	0.00118	CcSEcCtD
Pazopanib—Oedema peripheral—Temozolomide—skin cancer	9.25e-05	0.00117	CcSEcCtD
Pazopanib—Cardiac failure—Docetaxel—skin cancer	9.25e-05	0.00117	CcSEcCtD
Pazopanib—Pruritus—Vemurafenib—skin cancer	9.23e-05	0.00117	CcSEcCtD
Pazopanib—Connective tissue disorder—Temozolomide—skin cancer	9.23e-05	0.00117	CcSEcCtD
Pazopanib—Lethargy—Docetaxel—skin cancer	9.21e-05	0.00117	CcSEcCtD
Pazopanib—Urethral disorder—Temozolomide—skin cancer	9.2e-05	0.00117	CcSEcCtD
Pazopanib—Alopecia—Dactinomycin—skin cancer	9.17e-05	0.00116	CcSEcCtD
Pazopanib—Gastrointestinal pain—Imiquimod—skin cancer	9.1e-05	0.00115	CcSEcCtD
Pazopanib—Epistaxis—Fluorouracil—skin cancer	9.09e-05	0.00115	CcSEcCtD
Pazopanib—Hyponatraemia—Docetaxel—skin cancer	9.06e-05	0.00115	CcSEcCtD
Pazopanib—Erythema—Dactinomycin—skin cancer	9.04e-05	0.00115	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Docetaxel—skin cancer	9.02e-05	0.00114	CcSEcCtD
Pazopanib—Anaemia—Bleomycin—skin cancer	8.95e-05	0.00114	CcSEcCtD
Pazopanib—Diarrhoea—Vemurafenib—skin cancer	8.93e-05	0.00113	CcSEcCtD
Pazopanib—Abdominal pain—Imiquimod—skin cancer	8.8e-05	0.00112	CcSEcCtD
Pazopanib—Eye disorder—Temozolomide—skin cancer	8.77e-05	0.00111	CcSEcCtD
Pazopanib—Flushing—Temozolomide—skin cancer	8.71e-05	0.0011	CcSEcCtD
Pazopanib—Cardiac disorder—Temozolomide—skin cancer	8.71e-05	0.0011	CcSEcCtD
Pazopanib—Haemoglobin—Fluorouracil—skin cancer	8.69e-05	0.0011	CcSEcCtD
Pazopanib—Leukopenia—Bleomycin—skin cancer	8.67e-05	0.0011	CcSEcCtD
Pazopanib—Haemorrhage—Fluorouracil—skin cancer	8.65e-05	0.0011	CcSEcCtD
Pazopanib—Dizziness—Vemurafenib—skin cancer	8.63e-05	0.00109	CcSEcCtD
Pazopanib—Hypoaesthesia—Fluorouracil—skin cancer	8.61e-05	0.00109	CcSEcCtD
Pazopanib—Angiopathy—Temozolomide—skin cancer	8.52e-05	0.00108	CcSEcCtD
Pazopanib—Mediastinal disorder—Temozolomide—skin cancer	8.46e-05	0.00107	CcSEcCtD
Pazopanib—Cough—Bleomycin—skin cancer	8.45e-05	0.00107	CcSEcCtD
Pazopanib—Chills—Temozolomide—skin cancer	8.42e-05	0.00107	CcSEcCtD
Pazopanib—MAP2K5—lymph node—skin cancer	8.4e-05	0.00145	CbGeAlD
Pazopanib—KDR—lymph node—skin cancer	8.4e-05	0.00145	CbGeAlD
Pazopanib—Dehydration—Docetaxel—skin cancer	8.39e-05	0.00106	CcSEcCtD
Pazopanib—Anaemia—Dactinomycin—skin cancer	8.35e-05	0.00106	CcSEcCtD
Pazopanib—Liver function test abnormal—Docetaxel—skin cancer	8.33e-05	0.00106	CcSEcCtD
Pazopanib—Vomiting—Vemurafenib—skin cancer	8.3e-05	0.00105	CcSEcCtD
Pazopanib—Alopecia—Temozolomide—skin cancer	8.3e-05	0.00105	CcSEcCtD
Pazopanib—Dry skin—Docetaxel—skin cancer	8.27e-05	0.00105	CcSEcCtD
Pazopanib—Chest pain—Bleomycin—skin cancer	8.25e-05	0.00105	CcSEcCtD
Pazopanib—Myalgia—Bleomycin—skin cancer	8.25e-05	0.00105	CcSEcCtD
Pazopanib—Abdominal pain upper—Docetaxel—skin cancer	8.24e-05	0.00104	CcSEcCtD
Pazopanib—Rash—Vemurafenib—skin cancer	8.23e-05	0.00104	CcSEcCtD
Pazopanib—Mental disorder—Temozolomide—skin cancer	8.22e-05	0.00104	CcSEcCtD
Pazopanib—Dermatitis—Vemurafenib—skin cancer	8.22e-05	0.00104	CcSEcCtD
Pazopanib—CSF1R—lymph node—skin cancer	8.2e-05	0.00141	CbGeAlD
Pazopanib—Headache—Vemurafenib—skin cancer	8.18e-05	0.00104	CcSEcCtD
Pazopanib—Malnutrition—Temozolomide—skin cancer	8.17e-05	0.00104	CcSEcCtD
Pazopanib—Erythema—Temozolomide—skin cancer	8.17e-05	0.00104	CcSEcCtD
Pazopanib—ABCG2—mammalian vulva—skin cancer	8.16e-05	0.00141	CbGeAlD
Pazopanib—Breast disorder—Docetaxel—skin cancer	8.16e-05	0.00103	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Docetaxel—skin cancer	8.13e-05	0.00103	CcSEcCtD
Pazopanib—Leukopenia—Dactinomycin—skin cancer	8.09e-05	0.00103	CcSEcCtD
Pazopanib—Nasopharyngitis—Docetaxel—skin cancer	8.07e-05	0.00102	CcSEcCtD
Pazopanib—Dysgeusia—Temozolomide—skin cancer	8e-05	0.00101	CcSEcCtD
Pazopanib—Asthenia—Imiquimod—skin cancer	7.99e-05	0.00101	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Docetaxel—skin cancer	7.96e-05	0.00101	CcSEcCtD
Pazopanib—Oedema—Bleomycin—skin cancer	7.91e-05	0.001	CcSEcCtD
Pazopanib—Pruritus—Imiquimod—skin cancer	7.87e-05	0.000998	CcSEcCtD
Pazopanib—Infection—Bleomycin—skin cancer	7.86e-05	0.000996	CcSEcCtD
Pazopanib—Nausea—Vemurafenib—skin cancer	7.75e-05	0.000983	CcSEcCtD
Pazopanib—Thrombocytopenia—Bleomycin—skin cancer	7.74e-05	0.000981	CcSEcCtD
Pazopanib—Vision blurred—Temozolomide—skin cancer	7.7e-05	0.000976	CcSEcCtD
Pazopanib—Myalgia—Dactinomycin—skin cancer	7.69e-05	0.000975	CcSEcCtD
Pazopanib—Alopecia—Fluorouracil—skin cancer	7.64e-05	0.000969	CcSEcCtD
Pazopanib—Diarrhoea—Imiquimod—skin cancer	7.62e-05	0.000965	CcSEcCtD
Pazopanib—Anaemia—Temozolomide—skin cancer	7.55e-05	0.000958	CcSEcCtD
Pazopanib—Anorexia—Bleomycin—skin cancer	7.54e-05	0.000955	CcSEcCtD
Pazopanib—Erythema—Fluorouracil—skin cancer	7.53e-05	0.000955	CcSEcCtD
Pazopanib—KIT—lymph node—skin cancer	7.44e-05	0.00128	CbGeAlD
Pazopanib—Oedema—Dactinomycin—skin cancer	7.37e-05	0.000935	CcSEcCtD
Pazopanib—Dizziness—Imiquimod—skin cancer	7.36e-05	0.000933	CcSEcCtD
Pazopanib—Infection—Dactinomycin—skin cancer	7.33e-05	0.000929	CcSEcCtD
Pazopanib—Leukopenia—Temozolomide—skin cancer	7.32e-05	0.000927	CcSEcCtD
Pazopanib—Neutropenia—Docetaxel—skin cancer	7.29e-05	0.000925	CcSEcCtD
Pazopanib—PDGFRB—lymph node—skin cancer	7.27e-05	0.00125	CbGeAlD
Pazopanib—Thrombocytopenia—Dactinomycin—skin cancer	7.22e-05	0.000915	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Bleomycin—skin cancer	7.2e-05	0.000913	CcSEcCtD
Pazopanib—CYP2C8—female reproductive system—skin cancer	7.18e-05	0.00124	CbGeAlD
Pazopanib—Cough—Temozolomide—skin cancer	7.13e-05	0.000904	CcSEcCtD
Pazopanib—Paraesthesia—Bleomycin—skin cancer	7.1e-05	0.0009	CcSEcCtD
Pazopanib—Vision blurred—Fluorouracil—skin cancer	7.1e-05	0.0009	CcSEcCtD
Pazopanib—Vomiting—Imiquimod—skin cancer	7.08e-05	0.000897	CcSEcCtD
Pazopanib—Weight decreased—Docetaxel—skin cancer	7.06e-05	0.000895	CcSEcCtD
Pazopanib—Hypertension—Temozolomide—skin cancer	7.06e-05	0.000894	CcSEcCtD
Pazopanib—Dyspnoea—Bleomycin—skin cancer	7.05e-05	0.000894	CcSEcCtD
Pazopanib—Anorexia—Dactinomycin—skin cancer	7.03e-05	0.000891	CcSEcCtD
Pazopanib—Rash—Imiquimod—skin cancer	7.02e-05	0.00089	CcSEcCtD
Pazopanib—Dermatitis—Imiquimod—skin cancer	7.01e-05	0.000889	CcSEcCtD
Pazopanib—Headache—Imiquimod—skin cancer	6.97e-05	0.000884	CcSEcCtD
Pazopanib—Anaemia—Fluorouracil—skin cancer	6.96e-05	0.000882	CcSEcCtD
Pazopanib—Myalgia—Temozolomide—skin cancer	6.96e-05	0.000882	CcSEcCtD
Pazopanib—Arthralgia—Temozolomide—skin cancer	6.96e-05	0.000882	CcSEcCtD
Pazopanib—Infestation—Docetaxel—skin cancer	6.95e-05	0.000882	CcSEcCtD
Pazopanib—Infestation NOS—Docetaxel—skin cancer	6.95e-05	0.000882	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	6.91e-05	0.000876	CcSEcCtD
Pazopanib—Decreased appetite—Bleomycin—skin cancer	6.87e-05	0.000871	CcSEcCtD
Pazopanib—Acute coronary syndrome—Docetaxel—skin cancer	6.86e-05	0.000869	CcSEcCtD
Pazopanib—Myocardial infarction—Docetaxel—skin cancer	6.82e-05	0.000864	CcSEcCtD
Pazopanib—Dry mouth—Temozolomide—skin cancer	6.8e-05	0.000863	CcSEcCtD
Pazopanib—Stomatitis—Docetaxel—skin cancer	6.78e-05	0.000859	CcSEcCtD
Pazopanib—Jaundice—Docetaxel—skin cancer	6.78e-05	0.000859	CcSEcCtD
Pazopanib—Pain—Bleomycin—skin cancer	6.76e-05	0.000857	CcSEcCtD
Pazopanib—Leukopenia—Fluorouracil—skin cancer	6.74e-05	0.000854	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Dactinomycin—skin cancer	6.72e-05	0.000852	CcSEcCtD
Pazopanib—Oedema—Temozolomide—skin cancer	6.67e-05	0.000846	CcSEcCtD
Pazopanib—Infection—Temozolomide—skin cancer	6.63e-05	0.00084	CcSEcCtD
Pazopanib—Nausea—Imiquimod—skin cancer	6.61e-05	0.000838	CcSEcCtD
Pazopanib—Hepatobiliary disease—Docetaxel—skin cancer	6.58e-05	0.000834	CcSEcCtD
Pazopanib—Epistaxis—Docetaxel—skin cancer	6.56e-05	0.000832	CcSEcCtD
Pazopanib—Nervous system disorder—Temozolomide—skin cancer	6.54e-05	0.000829	CcSEcCtD
Pazopanib—Thrombocytopenia—Temozolomide—skin cancer	6.53e-05	0.000828	CcSEcCtD
Pazopanib—Skin disorder—Temozolomide—skin cancer	6.48e-05	0.000821	CcSEcCtD
Pazopanib—Hyperhidrosis—Temozolomide—skin cancer	6.45e-05	0.000817	CcSEcCtD
Pazopanib—Myalgia—Fluorouracil—skin cancer	6.41e-05	0.000813	CcSEcCtD
Pazopanib—Chest pain—Fluorouracil—skin cancer	6.41e-05	0.000813	CcSEcCtD
Pazopanib—Decreased appetite—Dactinomycin—skin cancer	6.41e-05	0.000813	CcSEcCtD
Pazopanib—Fatigue—Dactinomycin—skin cancer	6.36e-05	0.000806	CcSEcCtD
Pazopanib—Anorexia—Temozolomide—skin cancer	6.36e-05	0.000806	CcSEcCtD
Pazopanib—Pain—Dactinomycin—skin cancer	6.31e-05	0.000799	CcSEcCtD
Pazopanib—Haemoglobin—Docetaxel—skin cancer	6.27e-05	0.000795	CcSEcCtD
Pazopanib—Haemorrhage—Docetaxel—skin cancer	6.24e-05	0.000791	CcSEcCtD
Pazopanib—Hypoaesthesia—Docetaxel—skin cancer	6.21e-05	0.000787	CcSEcCtD
Pazopanib—Urinary tract disorder—Docetaxel—skin cancer	6.17e-05	0.000782	CcSEcCtD
Pazopanib—Oedema peripheral—Docetaxel—skin cancer	6.15e-05	0.00078	CcSEcCtD
Pazopanib—Oedema—Fluorouracil—skin cancer	6.15e-05	0.000779	CcSEcCtD
Pazopanib—Connective tissue disorder—Docetaxel—skin cancer	6.13e-05	0.000778	CcSEcCtD
Pazopanib—Urethral disorder—Docetaxel—skin cancer	6.12e-05	0.000776	CcSEcCtD
Pazopanib—Infection—Fluorouracil—skin cancer	6.11e-05	0.000774	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Temozolomide—skin cancer	6.08e-05	0.00077	CcSEcCtD
Pazopanib—Insomnia—Temozolomide—skin cancer	6.03e-05	0.000765	CcSEcCtD
Pazopanib—Gastrointestinal pain—Dactinomycin—skin cancer	6.03e-05	0.000764	CcSEcCtD
Pazopanib—Nervous system disorder—Fluorouracil—skin cancer	6.03e-05	0.000764	CcSEcCtD
Pazopanib—Thrombocytopenia—Fluorouracil—skin cancer	6.02e-05	0.000763	CcSEcCtD
Pazopanib—Paraesthesia—Temozolomide—skin cancer	5.99e-05	0.000759	CcSEcCtD
Pazopanib—Dyspnoea—Temozolomide—skin cancer	5.95e-05	0.000754	CcSEcCtD
Pazopanib—Somnolence—Temozolomide—skin cancer	5.93e-05	0.000752	CcSEcCtD
Pazopanib—Dyspepsia—Temozolomide—skin cancer	5.87e-05	0.000744	CcSEcCtD
Pazopanib—Anorexia—Fluorouracil—skin cancer	5.86e-05	0.000743	CcSEcCtD
Pazopanib—Eye disorder—Docetaxel—skin cancer	5.83e-05	0.00074	CcSEcCtD
Pazopanib—Abdominal pain—Dactinomycin—skin cancer	5.83e-05	0.000739	CcSEcCtD
Pazopanib—Decreased appetite—Temozolomide—skin cancer	5.8e-05	0.000735	CcSEcCtD
Pazopanib—Flushing—Docetaxel—skin cancer	5.79e-05	0.000735	CcSEcCtD
Pazopanib—Cardiac disorder—Docetaxel—skin cancer	5.79e-05	0.000735	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Temozolomide—skin cancer	5.76e-05	0.00073	CcSEcCtD
Pazopanib—Fatigue—Temozolomide—skin cancer	5.75e-05	0.000729	CcSEcCtD
Pazopanib—Pain—Temozolomide—skin cancer	5.7e-05	0.000723	CcSEcCtD
Pazopanib—Asthenia—Bleomycin—skin cancer	5.67e-05	0.000719	CcSEcCtD
Pazopanib—Angiopathy—Docetaxel—skin cancer	5.66e-05	0.000718	CcSEcCtD
Pazopanib—Mediastinal disorder—Docetaxel—skin cancer	5.63e-05	0.000713	CcSEcCtD
Pazopanib—Chills—Docetaxel—skin cancer	5.6e-05	0.00071	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Fluorouracil—skin cancer	5.6e-05	0.00071	CcSEcCtD
Pazopanib—Pruritus—Bleomycin—skin cancer	5.59e-05	0.000709	CcSEcCtD
Pazopanib—Insomnia—Fluorouracil—skin cancer	5.56e-05	0.000705	CcSEcCtD
Pazopanib—Paraesthesia—Fluorouracil—skin cancer	5.52e-05	0.0007	CcSEcCtD
Pazopanib—Alopecia—Docetaxel—skin cancer	5.52e-05	0.000699	CcSEcCtD
Pazopanib—Dyspnoea—Fluorouracil—skin cancer	5.48e-05	0.000695	CcSEcCtD
Pazopanib—Mental disorder—Docetaxel—skin cancer	5.47e-05	0.000693	CcSEcCtD
Pazopanib—Somnolence—Fluorouracil—skin cancer	5.46e-05	0.000693	CcSEcCtD
Pazopanib—Gastrointestinal pain—Temozolomide—skin cancer	5.45e-05	0.000691	CcSEcCtD
Pazopanib—Erythema—Docetaxel—skin cancer	5.43e-05	0.000689	CcSEcCtD
Pazopanib—Malnutrition—Docetaxel—skin cancer	5.43e-05	0.000689	CcSEcCtD
Pazopanib—Dyspepsia—Fluorouracil—skin cancer	5.41e-05	0.000686	CcSEcCtD
Pazopanib—Decreased appetite—Fluorouracil—skin cancer	5.34e-05	0.000677	CcSEcCtD
Pazopanib—Dysgeusia—Docetaxel—skin cancer	5.32e-05	0.000675	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Fluorouracil—skin cancer	5.31e-05	0.000673	CcSEcCtD
Pazopanib—Asthenia—Dactinomycin—skin cancer	5.29e-05	0.000671	CcSEcCtD
Pazopanib—Abdominal pain—Temozolomide—skin cancer	5.27e-05	0.000668	CcSEcCtD
Pazopanib—Pain—Fluorouracil—skin cancer	5.26e-05	0.000666	CcSEcCtD
Pazopanib—Muscle spasms—Docetaxel—skin cancer	5.23e-05	0.000662	CcSEcCtD
Pazopanib—Diarrhoea—Dactinomycin—skin cancer	5.05e-05	0.00064	CcSEcCtD
Pazopanib—Vomiting—Bleomycin—skin cancer	5.03e-05	0.000637	CcSEcCtD
Pazopanib—Anaemia—Docetaxel—skin cancer	5.02e-05	0.000637	CcSEcCtD
Pazopanib—Rash—Bleomycin—skin cancer	4.99e-05	0.000632	CcSEcCtD
Pazopanib—Dermatitis—Bleomycin—skin cancer	4.98e-05	0.000631	CcSEcCtD
Pazopanib—Syncope—Docetaxel—skin cancer	4.87e-05	0.000618	CcSEcCtD
Pazopanib—CYP3A4—female reproductive system—skin cancer	4.87e-05	0.000839	CbGeAlD
Pazopanib—Leukopenia—Docetaxel—skin cancer	4.86e-05	0.000617	CcSEcCtD
Pazopanib—CYP2D6—female reproductive system—skin cancer	4.79e-05	0.000826	CbGeAlD
Pazopanib—Asthenia—Temozolomide—skin cancer	4.79e-05	0.000607	CcSEcCtD
Pazopanib—Loss of consciousness—Docetaxel—skin cancer	4.78e-05	0.000606	CcSEcCtD
Pazopanib—Cough—Docetaxel—skin cancer	4.74e-05	0.000601	CcSEcCtD
Pazopanib—Pruritus—Temozolomide—skin cancer	4.72e-05	0.000598	CcSEcCtD
Pazopanib—Nausea—Bleomycin—skin cancer	4.7e-05	0.000595	CcSEcCtD
Pazopanib—Hypertension—Docetaxel—skin cancer	4.69e-05	0.000595	CcSEcCtD
Pazopanib—Vomiting—Dactinomycin—skin cancer	4.69e-05	0.000594	CcSEcCtD
Pazopanib—Rash—Dactinomycin—skin cancer	4.65e-05	0.000589	CcSEcCtD
Pazopanib—ABCB1—epithelium—skin cancer	4.64e-05	0.000799	CbGeAlD
Pazopanib—Chest pain—Docetaxel—skin cancer	4.63e-05	0.000587	CcSEcCtD
Pazopanib—Arthralgia—Docetaxel—skin cancer	4.63e-05	0.000587	CcSEcCtD
Pazopanib—Myalgia—Docetaxel—skin cancer	4.63e-05	0.000587	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	4.6e-05	0.000583	CcSEcCtD
Pazopanib—Diarrhoea—Temozolomide—skin cancer	4.56e-05	0.000579	CcSEcCtD
Pazopanib—Dry mouth—Docetaxel—skin cancer	4.53e-05	0.000574	CcSEcCtD
Pazopanib—Oedema—Docetaxel—skin cancer	4.44e-05	0.000562	CcSEcCtD
Pazopanib—Dizziness—Temozolomide—skin cancer	4.41e-05	0.000559	CcSEcCtD
Pazopanib—Infection—Docetaxel—skin cancer	4.41e-05	0.000559	CcSEcCtD
Pazopanib—Nausea—Dactinomycin—skin cancer	4.38e-05	0.000555	CcSEcCtD
Pazopanib—Shock—Docetaxel—skin cancer	4.36e-05	0.000553	CcSEcCtD
Pazopanib—Nervous system disorder—Docetaxel—skin cancer	4.35e-05	0.000551	CcSEcCtD
Pazopanib—Pruritus—Fluorouracil—skin cancer	4.35e-05	0.000551	CcSEcCtD
Pazopanib—Thrombocytopenia—Docetaxel—skin cancer	4.34e-05	0.000551	CcSEcCtD
Pazopanib—Skin disorder—Docetaxel—skin cancer	4.31e-05	0.000546	CcSEcCtD
Pazopanib—Vomiting—Temozolomide—skin cancer	4.24e-05	0.000538	CcSEcCtD
Pazopanib—Anorexia—Docetaxel—skin cancer	4.23e-05	0.000536	CcSEcCtD
Pazopanib—Rash—Temozolomide—skin cancer	4.21e-05	0.000533	CcSEcCtD
Pazopanib—Diarrhoea—Fluorouracil—skin cancer	4.2e-05	0.000533	CcSEcCtD
Pazopanib—Dermatitis—Temozolomide—skin cancer	4.2e-05	0.000533	CcSEcCtD
Pazopanib—Headache—Temozolomide—skin cancer	4.18e-05	0.00053	CcSEcCtD
Pazopanib—ABCG2—lymph node—skin cancer	4.09e-05	0.000705	CbGeAlD
Pazopanib—Dizziness—Fluorouracil—skin cancer	4.06e-05	0.000515	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Docetaxel—skin cancer	4.04e-05	0.000512	CcSEcCtD
Pazopanib—ABCB1—mammalian vulva—skin cancer	4.02e-05	0.000693	CbGeAlD
Pazopanib—Insomnia—Docetaxel—skin cancer	4.01e-05	0.000509	CcSEcCtD
Pazopanib—CYP2D6—head—skin cancer	4e-05	0.00069	CbGeAlD
Pazopanib—Paraesthesia—Docetaxel—skin cancer	3.98e-05	0.000505	CcSEcCtD
Pazopanib—Nausea—Temozolomide—skin cancer	3.96e-05	0.000502	CcSEcCtD
Pazopanib—Dyspnoea—Docetaxel—skin cancer	3.95e-05	0.000501	CcSEcCtD
Pazopanib—Somnolence—Docetaxel—skin cancer	3.94e-05	0.0005	CcSEcCtD
Pazopanib—Vomiting—Fluorouracil—skin cancer	3.91e-05	0.000495	CcSEcCtD
Pazopanib—Dyspepsia—Docetaxel—skin cancer	3.9e-05	0.000495	CcSEcCtD
Pazopanib—Rash—Fluorouracil—skin cancer	3.87e-05	0.000491	CcSEcCtD
Pazopanib—Dermatitis—Fluorouracil—skin cancer	3.87e-05	0.000491	CcSEcCtD
Pazopanib—Decreased appetite—Docetaxel—skin cancer	3.86e-05	0.000489	CcSEcCtD
Pazopanib—Headache—Fluorouracil—skin cancer	3.85e-05	0.000488	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Docetaxel—skin cancer	3.83e-05	0.000485	CcSEcCtD
Pazopanib—Fatigue—Docetaxel—skin cancer	3.82e-05	0.000485	CcSEcCtD
Pazopanib—Pain—Docetaxel—skin cancer	3.79e-05	0.000481	CcSEcCtD
Pazopanib—Nausea—Fluorouracil—skin cancer	3.65e-05	0.000463	CcSEcCtD
Pazopanib—Gastrointestinal pain—Docetaxel—skin cancer	3.63e-05	0.00046	CcSEcCtD
Pazopanib—ABCB1—lymphoid tissue—skin cancer	3.57e-05	0.000616	CbGeAlD
Pazopanib—Abdominal pain—Docetaxel—skin cancer	3.51e-05	0.000445	CcSEcCtD
Pazopanib—ABCB1—female reproductive system—skin cancer	3.44e-05	0.000594	CbGeAlD
Pazopanib—Asthenia—Docetaxel—skin cancer	3.18e-05	0.000403	CcSEcCtD
Pazopanib—Pruritus—Docetaxel—skin cancer	3.14e-05	0.000398	CcSEcCtD
Pazopanib—Diarrhoea—Docetaxel—skin cancer	3.03e-05	0.000385	CcSEcCtD
Pazopanib—Dizziness—Docetaxel—skin cancer	2.93e-05	0.000372	CcSEcCtD
Pazopanib—ABCB1—head—skin cancer	2.88e-05	0.000496	CbGeAlD
Pazopanib—Vomiting—Docetaxel—skin cancer	2.82e-05	0.000358	CcSEcCtD
Pazopanib—Rash—Docetaxel—skin cancer	2.8e-05	0.000355	CcSEcCtD
Pazopanib—Dermatitis—Docetaxel—skin cancer	2.79e-05	0.000354	CcSEcCtD
Pazopanib—Headache—Docetaxel—skin cancer	2.78e-05	0.000352	CcSEcCtD
Pazopanib—Nausea—Docetaxel—skin cancer	2.63e-05	0.000334	CcSEcCtD
Pazopanib—ABCB1—lymph node—skin cancer	2.02e-05	0.000347	CbGeAlD
Pazopanib—FGF1—Innate Immune System—IL6—skin cancer	4.41e-06	6.43e-05	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—KRAS—skin cancer	4.41e-06	6.43e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—BRAF—skin cancer	4.38e-06	6.39e-05	CbGpPWpGaD
Pazopanib—LCK—Cytokine Signaling in Immune system—IL6—skin cancer	4.38e-06	6.38e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—NRAS—skin cancer	4.37e-06	6.37e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—PTGS2—skin cancer	4.35e-06	6.35e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—KRAS—skin cancer	4.31e-06	6.29e-05	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—KRAS—skin cancer	4.31e-06	6.29e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling by NGF—IL6—skin cancer	4.3e-06	6.28e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—NRAS—skin cancer	4.28e-06	6.24e-05	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—KRAS—skin cancer	4.23e-06	6.17e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CSPG4—skin cancer	4.23e-06	6.17e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—NRAS—skin cancer	4.19e-06	6.12e-05	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—TP53—skin cancer	4.19e-06	6.11e-05	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—KRAS—skin cancer	4.18e-06	6.1e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—KRAS—skin cancer	4.17e-06	6.09e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—KRAS—skin cancer	4.17e-06	6.08e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—BRAF—skin cancer	4.16e-06	6.07e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—BRAF—skin cancer	4.15e-06	6.05e-05	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—NRAS—skin cancer	4.11e-06	5.99e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—KRAS—skin cancer	4.09e-06	5.96e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—NRAS—skin cancer	4.08e-06	5.95e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—BRAF—skin cancer	4.06e-06	5.92e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—ERCC2—skin cancer	4.04e-06	5.89e-05	CbGpPWpGaD
Pazopanib—FGFR1—Developmental Biology—HRAS—skin cancer	4.03e-06	5.87e-05	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—KRAS—skin cancer	4.02e-06	5.86e-05	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—HRAS—skin cancer	4.01e-06	5.85e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—KRAS—skin cancer	4.01e-06	5.84e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—FOXO4—skin cancer	3.97e-06	5.79e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—BRAF—skin cancer	3.96e-06	5.77e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TERT—skin cancer	3.95e-06	5.75e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—NRAS—skin cancer	3.89e-06	5.68e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TERT—skin cancer	3.87e-06	5.65e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—ERCC2—skin cancer	3.86e-06	5.63e-05	CbGpPWpGaD
Pazopanib—FGFR1—Developmental Biology—IL6—skin cancer	3.85e-06	5.62e-05	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—IL6—skin cancer	3.84e-06	5.59e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—TP53—skin cancer	3.83e-06	5.59e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	3.83e-06	5.58e-05	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—HRAS—skin cancer	3.82e-06	5.56e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—KRAS—skin cancer	3.8e-06	5.54e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—TERT—skin cancer	3.79e-06	5.52e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—BRAF—skin cancer	3.78e-06	5.51e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—KRAS—skin cancer	3.76e-06	5.48e-05	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—HRAS—skin cancer	3.75e-06	5.46e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—NRAS—skin cancer	3.74e-06	5.45e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—BRAF—skin cancer	3.74e-06	5.45e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—KRAS—skin cancer	3.68e-06	5.37e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TERT—skin cancer	3.68e-06	5.36e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—NRAS—skin cancer	3.67e-06	5.35e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TERT—skin cancer	3.67e-06	5.35e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—HRAS—skin cancer	3.67e-06	5.35e-05	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—HRAS—skin cancer	3.66e-06	5.34e-05	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—IL6—skin cancer	3.65e-06	5.33e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—TP53—skin cancer	3.63e-06	5.3e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—KRAS—skin cancer	3.61e-06	5.26e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—PTGS2—skin cancer	3.6e-06	5.26e-05	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—HRAS—skin cancer	3.6e-06	5.25e-05	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—IL6—skin cancer	3.59e-06	5.23e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CSPG4—skin cancer	3.58e-06	5.23e-05	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—HRAS—skin cancer	3.56e-06	5.19e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—HRAS—skin cancer	3.55e-06	5.17e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—HRAS—skin cancer	3.54e-06	5.17e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—ERCC2—skin cancer	3.54e-06	5.16e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—PTGS2—skin cancer	3.54e-06	5.16e-05	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—KRAS—skin cancer	3.53e-06	5.15e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—KRAS—skin cancer	3.51e-06	5.12e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—IL6—skin cancer	3.51e-06	5.12e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—NRAS—skin cancer	3.5e-06	5.11e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ENO2—skin cancer	3.5e-06	5.11e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—HRAS—skin cancer	3.47e-06	5.07e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PLIN2—skin cancer	3.43e-06	5e-05	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—HRAS—skin cancer	3.41e-06	4.98e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—HRAS—skin cancer	3.41e-06	4.97e-05	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—IL6—skin cancer	3.4e-06	4.96e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	3.4e-06	4.96e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—IL6—skin cancer	3.39e-06	4.95e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—IL6—skin cancer	3.39e-06	4.94e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—NRAS—skin cancer	3.39e-06	4.94e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—NRAS—skin cancer	3.37e-06	4.91e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—PTGS2—skin cancer	3.36e-06	4.9e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—KRAS—skin cancer	3.35e-06	4.89e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—PTGS2—skin cancer	3.35e-06	4.89e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TERT—skin cancer	3.3e-06	4.82e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—ERCC2—skin cancer	3.28e-06	4.78e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TERT—skin cancer	3.24e-06	4.72e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—HRAS—skin cancer	3.23e-06	4.71e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—KRAS—skin cancer	3.22e-06	4.69e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—HRAS—skin cancer	3.2e-06	4.66e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—KRAS—skin cancer	3.16e-06	4.61e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—HRAS—skin cancer	3.13e-06	4.56e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—BRAF—skin cancer	3.12e-06	4.56e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—IL6—skin cancer	3.09e-06	4.51e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—BRAF—skin cancer	3.07e-06	4.48e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—HRAS—skin cancer	3.07e-06	4.47e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—IL6—skin cancer	3.06e-06	4.46e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ENO2—skin cancer	3.05e-06	4.45e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—NRAS—skin cancer	3.04e-06	4.43e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—PTGS2—skin cancer	3.02e-06	4.4e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—KRAS—skin cancer	3.02e-06	4.4e-05	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—HRAS—skin cancer	3e-06	4.38e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—BRAF—skin cancer	3e-06	4.37e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—IL6—skin cancer	2.99e-06	4.37e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—NRAS—skin cancer	2.98e-06	4.35e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—HRAS—skin cancer	2.98e-06	4.35e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—TP53—skin cancer	2.98e-06	4.34e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—KRAS—skin cancer	2.92e-06	4.25e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—BRAF—skin cancer	2.91e-06	4.25e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—BRAF—skin cancer	2.9e-06	4.24e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—KRAS—skin cancer	2.9e-06	4.22e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ENO2—skin cancer	2.87e-06	4.19e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—TP53—skin cancer	2.86e-06	4.17e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—NRAS—skin cancer	2.86e-06	4.16e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—IL6—skin cancer	2.85e-06	4.16e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—HRAS—skin cancer	2.85e-06	4.15e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—NRAS—skin cancer	2.83e-06	4.13e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—NRAS—skin cancer	2.82e-06	4.12e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—NRAS—skin cancer	2.8e-06	4.09e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CSPG4—skin cancer	2.77e-06	4.03e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—NRAS—skin cancer	2.75e-06	4.02e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.74e-06	3.99e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—HRAS—skin cancer	2.73e-06	3.99e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—HRAS—skin cancer	2.68e-06	3.92e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TERT—skin cancer	2.65e-06	3.87e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—IL6—skin cancer	2.62e-06	3.82e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—BRAF—skin cancer	2.62e-06	3.82e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—KRAS—skin cancer	2.61e-06	3.81e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—NRAS—skin cancer	2.61e-06	3.81e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—NRAS—skin cancer	2.61e-06	3.8e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—IL6—skin cancer	2.57e-06	3.75e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—KRAS—skin cancer	2.57e-06	3.74e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—HRAS—skin cancer	2.56e-06	3.74e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—BRAF—skin cancer	2.56e-06	3.74e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—NRAS—skin cancer	2.55e-06	3.72e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—NRAS—skin cancer	2.54e-06	3.71e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—NRAS—skin cancer	2.49e-06	3.63e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—NRAS—skin cancer	2.49e-06	3.63e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—HRAS—skin cancer	2.48e-06	3.62e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—HRAS—skin cancer	2.46e-06	3.59e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—KRAS—skin cancer	2.46e-06	3.58e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—IL6—skin cancer	2.45e-06	3.58e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—KRAS—skin cancer	2.44e-06	3.55e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ENO2—skin cancer	2.44e-06	3.55e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—KRAS—skin cancer	2.43e-06	3.54e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—PTGS2—skin cancer	2.42e-06	3.53e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—KRAS—skin cancer	2.41e-06	3.52e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—NRAS—skin cancer	2.37e-06	3.46e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—IL6—skin cancer	2.37e-06	3.46e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—KRAS—skin cancer	2.37e-06	3.46e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—NRAS—skin cancer	2.35e-06	3.43e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PTGS2—skin cancer	2.32e-06	3.38e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—KRAS—skin cancer	2.25e-06	3.28e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—KRAS—skin cancer	2.24e-06	3.27e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—HRAS—skin cancer	2.22e-06	3.24e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—KRAS—skin cancer	2.2e-06	3.2e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—KRAS—skin cancer	2.19e-06	3.19e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TP53—skin cancer	2.18e-06	3.19e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—HRAS—skin cancer	2.18e-06	3.18e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—KRAS—skin cancer	2.14e-06	3.13e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—KRAS—skin cancer	2.14e-06	3.12e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—IL6—skin cancer	2.13e-06	3.1e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTGS2—skin cancer	2.12e-06	3.1e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—BRAF—skin cancer	2.1e-06	3.06e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—HRAS—skin cancer	2.09e-06	3.05e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—IL6—skin cancer	2.09e-06	3.05e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—HRAS—skin cancer	2.07e-06	3.02e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—HRAS—skin cancer	2.07e-06	3.01e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—HRAS—skin cancer	2.05e-06	2.99e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—KRAS—skin cancer	2.04e-06	2.98e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—NRAS—skin cancer	2.04e-06	2.98e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ERCC2—skin cancer	2.03e-06	2.97e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—KRAS—skin cancer	2.02e-06	2.95e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—HRAS—skin cancer	2.01e-06	2.94e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—IL6—skin cancer	2e-06	2.92e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL6—skin cancer	1.98e-06	2.89e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL6—skin cancer	1.98e-06	2.88e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTGS2—skin cancer	1.97e-06	2.87e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—NRAS—skin cancer	1.96e-06	2.86e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—IL6—skin cancer	1.96e-06	2.86e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—skin cancer	1.95e-06	2.85e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—NRAS—skin cancer	1.93e-06	2.81e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—IL6—skin cancer	1.93e-06	2.81e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—HRAS—skin cancer	1.91e-06	2.79e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—HRAS—skin cancer	1.91e-06	2.78e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.9e-06	2.78e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—skin cancer	1.9e-06	2.77e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—NRAS—skin cancer	1.88e-06	2.75e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ENO2—skin cancer	1.88e-06	2.74e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—HRAS—skin cancer	1.87e-06	2.72e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HRAS—skin cancer	1.86e-06	2.71e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—NRAS—skin cancer	1.83e-06	2.67e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—IL6—skin cancer	1.83e-06	2.67e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—NRAS—skin cancer	1.83e-06	2.66e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—IL6—skin cancer	1.83e-06	2.66e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—HRAS—skin cancer	1.82e-06	2.66e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—HRAS—skin cancer	1.82e-06	2.65e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—skin cancer	1.82e-06	2.65e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IL6—skin cancer	1.79e-06	2.61e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL6—skin cancer	1.78e-06	2.6e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ERCC2—skin cancer	1.77e-06	2.58e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—KRAS—skin cancer	1.76e-06	2.56e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL6—skin cancer	1.74e-06	2.54e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL6—skin cancer	1.74e-06	2.54e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—HRAS—skin cancer	1.74e-06	2.53e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—HRAS—skin cancer	1.72e-06	2.51e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KRAS—skin cancer	1.69e-06	2.46e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ERCC2—skin cancer	1.67e-06	2.44e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL6—skin cancer	1.66e-06	2.42e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—KRAS—skin cancer	1.66e-06	2.42e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NRAS—skin cancer	1.64e-06	2.4e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—IL6—skin cancer	1.64e-06	2.4e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—KRAS—skin cancer	1.62e-06	2.37e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NRAS—skin cancer	1.61e-06	2.35e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KRAS—skin cancer	1.58e-06	2.3e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KRAS—skin cancer	1.57e-06	2.29e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—skin cancer	1.5e-06	2.19e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—HRAS—skin cancer	1.49e-06	2.18e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—skin cancer	1.48e-06	2.15e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—HRAS—skin cancer	1.44e-06	2.1e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL6—skin cancer	1.43e-06	2.08e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KRAS—skin cancer	1.42e-06	2.06e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ERCC2—skin cancer	1.41e-06	2.06e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—HRAS—skin cancer	1.41e-06	2.06e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—skin cancer	1.4e-06	2.04e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—skin cancer	1.4e-06	2.04e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KRAS—skin cancer	1.39e-06	2.02e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—HRAS—skin cancer	1.38e-06	2.01e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL6—skin cancer	1.37e-06	2.01e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL6—skin cancer	1.35e-06	1.97e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—HRAS—skin cancer	1.34e-06	1.95e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—HRAS—skin cancer	1.34e-06	1.95e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NRAS—skin cancer	1.32e-06	1.92e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—IL6—skin cancer	1.32e-06	1.92e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL6—skin cancer	1.28e-06	1.87e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL6—skin cancer	1.28e-06	1.86e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—skin cancer	1.26e-06	1.83e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—skin cancer	1.23e-06	1.8e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTGS2—skin cancer	1.22e-06	1.78e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HRAS—skin cancer	1.2e-06	1.75e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HRAS—skin cancer	1.18e-06	1.72e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL6—skin cancer	1.15e-06	1.68e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KRAS—skin cancer	1.14e-06	1.66e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL6—skin cancer	1.13e-06	1.64e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ERCC2—skin cancer	1.09e-06	1.59e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTGS2—skin cancer	1.06e-06	1.55e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—skin cancer	1.01e-06	1.47e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTGS2—skin cancer	1e-06	1.46e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HRAS—skin cancer	9.66e-07	1.41e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL6—skin cancer	9.24e-07	1.35e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTGS2—skin cancer	8.48e-07	1.24e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTGS2—skin cancer	6.55e-07	9.55e-06	CbGpPWpGaD
